Curative Biotechnology Inc (CUBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) has a cash flow conversion efficiency ratio of 0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-193.12K) by net assets ($-6.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Curative Biotechnology Inc for the company's overall valuation and market capitalisation.
Curative Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Curative Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Curative Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curative Biotechnology Inc ranked by their cash flow conversion efficiency. Explore Curative Biotechnology Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BHB Brauholding Bayern-Mitte AG
F:B9B
|
N/A |
|
Mountain Lake Acquisition Corp. Right
NASDAQ:MLACR
|
N/A |
|
Skin Elements Ltd
AU:SKN
|
-0.699x |
|
PEREGRINE GOLD LTD
F:9VA
|
N/A |
|
Intelicanna Ltd
TA:INTL
|
-0.023x |
|
OSR Holdings Inc
NASDAQ:OSRH
|
-0.019x |
|
Intelligent Bio Solutions Inc.
NASDAQ:INBS
|
-0.831x |
|
Lodestar Minerals Ltd
AU:LSR
|
3.339x |
Annual Cash Flow Conversion Efficiency for Curative Biotechnology Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Curative Biotechnology Inc from 2013 to 2025. View Curative Biotechnology Inc (CUBT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.09 Million | $-868.87K | 0.143x | -31.43% |
| 2024-12-31 | $-4.91 Million | $-1.02 Million | 0.208x | +34.46% |
| 2023-12-31 | $-3.14 Million | $-486.58K | 0.155x | +107.00% |
| 2022-12-31 | $-20.53 Million | $-1.54 Million | 0.075x | -23.70% |
| 2021-12-31 | $-16.36 Million | $-1.60 Million | 0.098x | +133.19% |
| 2020-12-31 | $-4.52 Million | $-190.09K | 0.042x | +9914.88% |
| 2019-12-31 | $-357.33K | $-150.00 | 0.000x | +92.90% |
| 2018-12-31 | $-689.28K | $-150.00 | 0.000x | -4.34% |
| 2017-12-31 | $-659.37K | $-150.00 | 0.000x | -97.54% |
| 2016-12-31 | $-636.38K | $-5.89K | 0.009x | +393.09% |
| 2015-12-31 | $-618.98K | $1.96K | -0.003x | -111.64% |
| 2014-12-31 | $-773.80K | $-20.99K | 0.027x | -46.45% |
| 2013-12-31 | $-704.28K | $-35.68K | 0.051x | -- |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more